CenterPoint Energy Inc.

5 days ago · seekingalpha.com

CenterPoint Energy remains a "Buy," underpinned by robust Houston metro growth and disciplined cost management. CNP raised 2023 EPS guidance to $1.90–$1.92 and initiated 2027 guidance at $2.07–$2.09, targeting 8%–9% long-term EPS growth. A $4 billion cap-ex increase and accelerated investments reflect strong underlying demand, especially in Houston Electric.

5 days ago · zacks.com

CNP beats Q3 2026 earnings and revenue estimates, with sales rising 10.2% year over year, and raises its full-year adjusted EPS guidance.

5 days ago · seekingalpha.com

CenterPoint Energy, Inc. (CNP) Q3 2026 Earnings Call Transcript

5 days ago · marketbeat.com

CenterPoint Energy NYSE: CNP raised its 2026 adjusted earnings guidance and expanded its long-term capital plan, citing accelerating customer demand in the Greater Houston area and additional investment needs across its electric transmission and distribution system.

5 days ago · zacks.com

Although the revenue and EPS for CenterPoint (CNP) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

6 days ago · zacks.com

CenterPoint Energy (CNP) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.5 per share a year ago.

6 days ago · businesswire.com

HOUSTON--(BUSINESS WIRE)--CenterPoint Energy, Inc. (NYSE: CNP), or “CenterPoint,” today reported net income of $331 million, or $0.50 per diluted share, on a GAAP basis for the third quarter of 2026, compared to $0.45 per diluted share in the comparable period of 2025. Non-GAAP EPS for the third quarter of 2026 was $0.53 per diluted share, compared to $0.50 per diluted share in the comparable period of 2025. These strong third quarter results were primarily driven by growth and rate recovery, w.

12 days ago · zacks.com

CNP's Q3 earnings are likely to benefit from grid investments, rising electricity demand and rate-base growth, while higher financing costs could offset gains.

13 days ago · zacks.com

CenterPoint (CNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

17 days ago · globenewswire.com

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.